[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity
Phio Pharmaceuticals Corp. director Patricia A. Bradford reported a change in beneficial ownership related to restricted stock units. The filing shows an acquisition of 18,800 shares of common stock issued to satisfy restricted stock units that will vest on the first annual anniversary of the grant. Following the reported transaction, Ms. Bradford beneficially owns 27,151 shares, a total that the filing indicates includes shares underlying unvested restricted stock units. The reported share counts have been adjusted to reflect prior reverse stock splits. The transaction was reported as an acquisition at $0 per share, consistent with issuance upon vesting of RSUs.
La consigliera di Phio Pharmaceuticals Corp., Patricia A. Bradford, ha segnalato una modifica della titolarità beneficiaria relativa a unità di azioni vincolate (RSU). La pratica mostra un'acquisizione di 18,800 azioni ordinarie emesse per soddisfare le RSU che si matureranno al primo anniversario annuale dell'assegnazione. Dopo la transazione riportata, la signora Bradford detiene beneficiamente 27,151 azioni, un totale che la pratica indica includere azioni su cui sono basate RSU non maturate. I conteggi azionari riportati sono stati adeguati per riflettere precedenti raggruppamenti azionari inversi. La transazione è stata riportata come un'acquisizione a $0 per azione, coerente con l’emissione al vesting delle RSU.
La directora de Phio Pharmaceuticals Corp., Patricia A. Bradford, informó un cambio en la titularidad beneficiosa relacionado con unidades de acciones restringidas. El formulario muestra una adquisición de 18,800 acciones comunes emitidas para satisfacer las RSU que vencerán en el primer aniversario del otorgamiento. Tras la operación reportada, la Sra. Bradford posee beneficiosamente 27,151 acciones, un total que la presentación indica que incluye acciones subyacentes a RSU no vestidas. Los montos de acciones reportados se han ajustado para reflejar anteriores divisiones inversas de acciones. La transacción se informó como una adquisición a $0 por acción, coherente con la emisión al vesting de las RSU.
Phio Pharmaceuticals Corp. 이사인 Patricia A. Bradford가 제한 주식 단위(RSU)와 관련된 유익권의 변경을 보고했습니다. 공시에는 그랜트의 첫 번째 연차가 만료될 때 vesting될 RSU를 충당하기 위해 발행된 18,800주 보통주를 취득한 것으로 표시되어 있습니다. 보고된 거래 후 브래드포드 여사는 27,151주를 유익하게 소유하고 있으며, 이는 미 vest RSU에 기초한 주식을 포함하는 합계로 공시에서 명시하고 있습니다. 보고된 주식 수치는 앞선 역분할을 반영하도록 조정되었습니다. 이 거래는 RSU의 vesting 시 발행되는 것과 일치하도록 주당 $0으로 취득으로 보고되었습니다.
La administratrice de Phio Pharmaceuticals Corp., Patricia A. Bradford, a signalé un changement de propriété bénéficiaire lié à des unités d’actions restreintes (RSU). Le dossier indique une acquisition de 18 800 actions ordinaires émises pour satisfaire des RSU qui vestent au premier anniversaire de l’octroi. Suite à la transaction signalée, Mme Bradford détient bénéficiellement 27 151 actions, un total que le dossier précise inclure des actions sous-jacentes à des RSU non encore vestes. Les chiffres d’actions rapportés ont été ajustés pour refléter les regroupements d’actions antérieurs inverses. La transaction a été déclarée comme une acquisition à $0 par action, conformément à l’émission lors du vesting des RSU.
Direktorin von Phio Pharmaceuticals Corp., Patricia A. Bradford, meldete eine Veränderung des wirtschaftlichen Eigentums im Zusammenhang mit Restricted Stock Units (RSUs). Die Einreichung zeigt einen Erwerb von 18.800 Stammaktien, die ausgegeben wurden, um RSUs zu erfüllen, die am ersten Jahrestag der Gewährung vesten werden. Nach der berichteten Transaktion besitzt Frau Bradford wirtschaftlich 27.151 Aktien, eine Summe, die in der Einreichung RSUs umfasst, die noch nicht vestet sind. Die berichteten Aktienzahlen wurden angepasst, um frühere Reverse-Stock-Splits zu berücksichtigen. Die Transaktion wurde als Erwerb zu $0 pro Aktie gemeldet, im Einklang mit der Emission bei Vesting der RSUs.
أفادت مديرة شركة Phio Pharmaceuticals Corp., باتريشيا أ. برادفورد، عن تغيير في الملكية المستفيدة متعلق بوحدات الأسهم المقيدة. تُظهر الإيداع عملية شراء لـ 18,800 سهمًا من الأسهم العادية صُدّرت لتلبية RSU التي ستتحقق عند السنة الأولى من المنحة. عقب المعاملة المبلغ عنها، تمتلك السيدة برادفورد بشكل مستفاد 27,151 سهمًا، وهو مجموع يذكره الإيداع ليشمل الأسهم الكامنة وراء RSU غيرvested. تم تعديل أعداد الأسهم المبلغ عنها لتعكس عمليات تقسيم الأسهم العكسي السابقة. أُبلغ عن المعاملة كعملية اكتساب بسعر $0 للسهم، بما يتماشى مع الإصدار عند vesting للـ RSU.
Phio Pharmaceuticals Corp. 的董事 Patricia A. Bradford 报告了与受限股票单位（RSU）相关的受益所有权变动。 文件显示为满足 RSU 将在授予后的第一个周年日归属而发行的 18,800 股普通股的取得。交易信息显示 Bradford 女士在此交易后实际持有 27,151 股，此总数包含未归属 RSU 的基础股票。所报股数已调整以反映之前的反向股票分割。该交易被报道为以每股 $0 的价格取得，与 RSU 归属时的发行一致。
- Director received 18,800 shares via restricted stock units, indicating continued alignment of management/director incentives with shareholders
- Total beneficial ownership reported as 27,151 shares, with disclosure that unvested RSUs are included, improving transparency
- Filing discloses adjustment for reverse stock splits, clarifying comparability of historical holdings
- None.
Insights
TL;DR: A director received RSU-based shares, modestly increasing her stake; this is a routine insider equity grant.
The reported acquisition of 18,800 shares reflects issuance tied to restricted stock units rather than an open-market purchase. Such grants are common for directors and key personnel and typically reflect compensation or retention rather than a direct signal of changed valuation expectations. The filing shows total beneficial ownership of 27,151 shares, including unvested RSUs; counts were adjusted for prior reverse stock splits, which recalibrates historical holdings but does not change economic ownership. Impact on capitalization and voting is likely immaterial unless cumulative holdings cross disclosure or control thresholds, which are not indicated here.
TL;DR: This is a standard director equity award disclosure with no indicated governance issues or unusual terms.
The Form 4 documents an equity issuance tied to RSUs that vest on a stated schedule (first anniversary of the grant). The report identifies the reporting person as a director and files as an individual reporting person. The explanation notes inclusion of unvested RSUs and adjustment for reverse stock splits, ensuring transparency in reported share counts. There is no indication of accelerated vesting, related-party transactions, or transfers that would raise governance concerns. This disclosure aligns with routine compensation-related reporting obligations under Section 16.
La consigliera di Phio Pharmaceuticals Corp., Patricia A. Bradford, ha segnalato una modifica della titolarità beneficiaria relativa a unità di azioni vincolate (RSU). La pratica mostra un'acquisizione di 18,800 azioni ordinarie emesse per soddisfare le RSU che si matureranno al primo anniversario annuale dell'assegnazione. Dopo la transazione riportata, la signora Bradford detiene beneficiamente 27,151 azioni, un totale che la pratica indica includere azioni su cui sono basate RSU non maturate. I conteggi azionari riportati sono stati adeguati per riflettere precedenti raggruppamenti azionari inversi. La transazione è stata riportata come un'acquisizione a $0 per azione, coerente con l’emissione al vesting delle RSU.
La directora de Phio Pharmaceuticals Corp., Patricia A. Bradford, informó un cambio en la titularidad beneficiosa relacionado con unidades de acciones restringidas. El formulario muestra una adquisición de 18,800 acciones comunes emitidas para satisfacer las RSU que vencerán en el primer aniversario del otorgamiento. Tras la operación reportada, la Sra. Bradford posee beneficiosamente 27,151 acciones, un total que la presentación indica que incluye acciones subyacentes a RSU no vestidas. Los montos de acciones reportados se han ajustado para reflejar anteriores divisiones inversas de acciones. La transacción se informó como una adquisición a $0 por acción, coherente con la emisión al vesting de las RSU.
Phio Pharmaceuticals Corp. 이사인 Patricia A. Bradford가 제한 주식 단위(RSU)와 관련된 유익권의 변경을 보고했습니다. 공시에는 그랜트의 첫 번째 연차가 만료될 때 vesting될 RSU를 충당하기 위해 발행된 18,800주 보통주를 취득한 것으로 표시되어 있습니다. 보고된 거래 후 브래드포드 여사는 27,151주를 유익하게 소유하고 있으며, 이는 미 vest RSU에 기초한 주식을 포함하는 합계로 공시에서 명시하고 있습니다. 보고된 주식 수치는 앞선 역분할을 반영하도록 조정되었습니다. 이 거래는 RSU의 vesting 시 발행되는 것과 일치하도록 주당 $0으로 취득으로 보고되었습니다.
La administratrice de Phio Pharmaceuticals Corp., Patricia A. Bradford, a signalé un changement de propriété bénéficiaire lié à des unités d’actions restreintes (RSU). Le dossier indique une acquisition de 18 800 actions ordinaires émises pour satisfaire des RSU qui vestent au premier anniversaire de l’octroi. Suite à la transaction signalée, Mme Bradford détient bénéficiellement 27 151 actions, un total que le dossier précise inclure des actions sous-jacentes à des RSU non encore vestes. Les chiffres d’actions rapportés ont été ajustés pour refléter les regroupements d’actions antérieurs inverses. La transaction a été déclarée comme une acquisition à $0 par action, conformément à l’émission lors du vesting des RSU.
Direktorin von Phio Pharmaceuticals Corp., Patricia A. Bradford, meldete eine Veränderung des wirtschaftlichen Eigentums im Zusammenhang mit Restricted Stock Units (RSUs). Die Einreichung zeigt einen Erwerb von 18.800 Stammaktien, die ausgegeben wurden, um RSUs zu erfüllen, die am ersten Jahrestag der Gewährung vesten werden. Nach der berichteten Transaktion besitzt Frau Bradford wirtschaftlich 27.151 Aktien, eine Summe, die in der Einreichung RSUs umfasst, die noch nicht vestet sind. Die berichteten Aktienzahlen wurden angepasst, um frühere Reverse-Stock-Splits zu berücksichtigen. Die Transaktion wurde als Erwerb zu $0 pro Aktie gemeldet, im Einklang mit der Emission bei Vesting der RSUs.
FAQ
What transaction did Patricia A. Bradford report on Form 4 for PHIO?
How many PHIO shares does the reporting person beneficially own after the transaction?
Were the reported PHIO shares issued for a purchase price?
Do the reported PHIO share counts reflect corporate actions like reverse splits?
What is the vesting condition for the RSUs reported on this PHIO Form 4?
